Most of the newly approved drugs and treatments for men with advanced prostate cancer are designed and approved to be used independently of other advanced prostate cancer treatments, other than with the continuation of standard androgen deprivation therapy (ADT). The newly approved drug, Xofigo, is different. It has been designed to supplement, or actually go [...]
It has been brought to my attention that when I wrote the August 8, 2013 post on Pharma Sponsored Assistance Programs, I neglected to mention another excellent assistance program for men with advanced prostate cancer. The Chronic Disease Fund (CDF) has two funds that might be of specific interest to men with castrate resistant prostate [...]
Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by [...]
There are a number of funds available to assist men with their treatment co-pays and to help cover travel for treatments. These funds receive their financial support from the drug companies (pharama) which make voluntary contributions. Within the overarching fund there are many disease specific funds that supply co-pay and or travel support for individuals. [...]
Enzalutamide (Xtandi) monotherapy induced striking declines in prostate-specific antigen (PSA) in a majority of patients with hormone-naive prostate cancer in a phase II trial, and this oral agent appears to have little effect on bone mineral density. If these findings are confirmed in a phase III trial, then enzalutamide may be an alternative to androgen [...]